TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04705480
Drug: Gabapentin 300mg
Normalized name: GABAPENTIN 300MG CAP
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 300 mg PO every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
Study: NCT04705480
Drug: Neither Pregabalin nor Gabapentin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive neither Pregabalin nor Gabapentin.
Study: NCT05216263
Drug: Atogepant
Normalized name: Atogepant
DrugBank: Atogepant (DB16098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT04177498
Drug: Rigosertib Sodium
Normalized name: Rigosertib
DrugBank: Rigosertib (DB12146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: given PO or 72 hour continuous infusion
Study: NCT06018883
Drug: Ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin C 900 mg/day, three times a day, orally.
Study: NCT06018883
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks
Study: NCT06018883
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
Study: NCT04124367
Drug: Cerebrolysin
Normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml once daily (+70 ml 0.9% saline)
Study: NCT05702944
Drug: Phenoxybenzamine
Normalized name: Phenoxybenzamine
DrugBank: Phenoxybenzamine (DB00925)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
Study: NCT05569577
Drug: estrogen and dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estrogen and dydrogesterone
Study: NCT05475873
Drug: Ondansetron 4 mg
Normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
Study: NCT05475873
Drug: Ondansetron 8 mg
Normalized name: ondansetron 8 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
Study: NCT05374356
Drug: Intrathecal bupivacaine and morphine
Normalized name: bupivacaine and meloxicam
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).
Study: NCT05243329
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg or 25 mg oral aqueous psilocybin solution
Study: NCT06217406
Drug: Intravenous acyclovir (ACYCLOVIR )
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized in the experimental arm will receive intravenous acyclovir at a dosing of 5 mg/kg/8 hours during 14 days (treatment will be stopped at ICU discharge).
Study: NCT04831944
Drug: parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: parsaclisib will be administered orally after 8 hours of fasting.
Study: NCT05253807
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 13.5 mg tablet
Study: NCT06332053
Drug: SY-5007
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SY-5007 80 mg, Tablets, 2 discrete single doses at Day 1 and Day 11
Study: NCT06510426
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mL of saline administered subcutaneously
Study: NCT05581719
Drug: Allocetra-OTS
Normalized name: Allocetra
DrugBank: Allocetra (DB16424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
Study: NCT05581719
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immune checkpoint inhibitor (anti-PD-1 antibody)
Study: NCT05581719
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitor (anti-PD-1 antibody)
Study: NCT05418946
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment of T2D and cardio-renal prevention
Study: NCT06332053
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 200 mg, Capsules, Day 8-Day 18
Study: NCT06388369
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 cycles of Ipilimumab 3mg/kg at 3 weeks intervals
Study: NCT06332053
Drug: SY-5007
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SY-5007 160 mg, Tablets, 2 discrete single doses at Day 1 and Day 16
Study: NCT06332053
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg, Capsules, Day 8-Day 21
Study: NCT06143631
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral letrozole 2.5mg/day
Study: NCT05128617
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 cycle of Paclitaxel
Study: NCT04723537
Drug: Part A: Upamostat 200 mg
DrugBank: Upamostat (DB13052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule comprising 200 mg of upamostat and 1 capsule comprising matching placebo.
Study: NCT04723537
Drug: Part A: Upamostat 400 mg
DrugBank: Upamostat (DB13052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules, each capsule comprising 200 mg of upamostat
Study: NCT04723537
Drug: Part B: Upamostat 200 or 400 mg
DrugBank: Upamostat (DB13052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on dose selection from Part A, Part B Upamostat will be EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days.
Study: NCT05027269
Drug: AOC 1001
Normalized name: AOC 1001
DrugBank: AOC 1001 (DB18620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOC 1001 will be administered by intravenous (IV) infusion.
Study: NCT06498908
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide, commonly known as laughing gas, is a colorless, non-flammable gas with a slightly sweet odor, used for its analgesic and anesthetic properties in medical and dental procedures to provide pain relief and sedation.
Study: NCT06498908
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen is a colorless, odorless gas essential for human respiration and used medically to treat conditions resulting from low oxygen levels in the blood. In this trial Oxygen is being used as a placebo.
Study: NCT05965570
Drug: Brensocatib
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets.
Study: NCT00002042
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06529497
Drug: Racecadotril
Normalized name: racecadotril
DrugBank: Racecadotril (DB11696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group will receive racecadotril+ORS+Zinc
Study: NCT00029796
Drug: soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05983302
Drug: Platelet-Rich Plasma-Fibrin Glue
Normalized name: Platelet Rich Plasma
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
Study: NCT05983302
Drug: Repairing Gel
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.
Study: NCT05983302
Drug: Repairing Gel and Platelet-Rich Plasma-Fibrin Glue
Normalized name: Platelet Rich Plasma
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
Study: NCT04837040
Drug: Paltusotine
Normalized name: Paltusotine
DrugBank: Paltusotine (DB16277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paltusotine, tablets, once daily by mouth
Study: NCT00002208
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002208
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002208
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002208
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00960817
Drug: Dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06027983
Drug: Chimeric receptor T-cells + Trastuzumab
Normalized name: B7-H3-specific chimeric antigen receptor T cells
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously.
Study: NCT06027983
Drug: Fludarabine and Cyclophosphosphamide
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion
Study: NCT05513976
Drug: febuxostat tablet
Normalized name: Febuxostat Tablets
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: febuxostat tablet 40mg or 60mg or 80mg based on prior medication
Study: NCT06454968
Drug: Orelabrutinib, obinutuzumab, lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orelabrutinib: 150mg qd d1-d21/C1-C6 obinutuzumab: 1000mg iv d1,d8,d15/c1, 1000mg iv d1/C2-C6 lenalidomide：25mg po qd d1-14/C1-C6 Orelabrutinib: 150mg qd d1-d28/C7-C12
Study: NCT06010667
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: With or without Envafolimab
Study: NCT06574022
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 30 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
Study: NCT06574022
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 20 cc of Exparel mixed with 10 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
Study: NCT05634512
Drug: Laronidase therapy and a stem cell transplant
Normalized name: Laronidase
DrugBank: Laronidase (DB00090)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: To identify key differences leading to variability in PK parameters for patients receiving IV laronidase therapy for the treatment of MPS-IH. There will be 12 samples per patient (6 pre-transplant and 6-post-transplant). Laronidase will be administered IV per protocol using standard dosing (0.58 mg/kg intravenously on a weekly basis), and six (n=6) blood samples will be collected over 24 hours for the determination of mononuclear cell lysates and plasma laronidase concentrations for a total of 18mL. The second PK monitoring will be obtained using the same PK design but following complete or near-completedonor derived myeloid engraftment which is evaluated at different time pointspost-HCT (day 30, day 42, day 60). The standard is to continue ERT through 8 weeks post-transplant.
Study: NCT06573424
Drug: anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who have been treated with anlotinib monotherapy
Study: NCT04885049
Drug: Racecadotril
Normalized name: racecadotril
DrugBank: Racecadotril (DB11696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti secretary
Study: NCT05926206
Drug: Devimistat
Normalized name: Devimistat
DrugBank: Devimistat (DB12109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3
Study: NCT06316323
Drug: Silver diamine fluoride
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 38% Silver Diamine Fluoride (SDF) is a topical antimicrobial and remineralizing agent which was cleared by the FDA as a Class II medical device to treat tooth sensitivity. In certain circumstances, SDF may be used as a non-restorative treatment to arrest carious lesions on primary and permanent teeth
Study: NCT06316323
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride varnish to apply on tooth surface, so that the tooth becomes more resistant to caries attack. The active ingredient of fluoride varnish is 5% sodium fluoride, (22,600 ppm fluoride)
Study: NCT04848974
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04848974
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given SC
Study: NCT04848974
Drug: Uproleselan
Normalized name: Uproleselan
DrugBank: Uproleselan (DB14829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05650229
Drug: KL1333
Normalized name: KL1333
DrugBank: KL1333 (DB17622)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT06171152
Drug: Liraglutide Pen Injector [Saxenda]
Normalized name: liraglutide Pen Injector [Saxenda]
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.
Study: NCT04797286
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.
Study: NCT06251388
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AK104（10.0 mg/kg，intravenous (IV) infusion，Q3W）maintained with no more than 1 year.
Study: NCT05383677
Drug: Anifrolumab
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
Study: NCT05476003
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will be premedicated with Midazolam (0.02mg/Kg).
Study: NCT05316857
Drug: Orelabrutinib + Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib + Rifampin
Study: NCT05316857
Drug: Orelabrutinib + Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orelabrutinib + Itraconazole
Study: NCT05582538
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
Study: NCT05582538
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg i.v. day 1 (q28)
Study: NCT05582538
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg/m2 i.v. day 1,8,15 (q28)
Study: NCT04752813
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for additional 6 cycles post BPM31510 treatment.
Study: NCT04892446
Drug: Magrolimab
Normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04892446
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered either SC or IV
Study: NCT04892446
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT04892446
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT04892446
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered either SC or IV
Study: NCT04892446
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT06091423
Drug: XELOX combined with Fruquintinib and Sintilimab
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX:Capecitabine：800mg/m2, po, bid, d1-14。Oxaliplatin：130mg/m2，ivgtt 2-6h，d1，q3w; Fruquintinib: 5 mg/d，qd po，d1-14，q3w; Sintilimab: 200mg d1, q3w
Study: NCT05174806
Drug: Topical Pravibismane
Normalized name: Pravibismane
DrugBank: Pravibismane (DB17784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Pravibismane
Study: NCT05509257
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
Study: NCT06562816
Drug: Trypsin-Chymotrypsin
Normalized name: TRYPSIN-CHYMOTRYPSIN
DrugBank: Chymotrypsin (DB09375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100000 IU
Study: NCT04523792
Drug: SUBLOCADE
Normalized name: Sublocade
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
Study: NCT05360615
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SGLT2 inhibitors
Study: NCT05327530
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Study: NCT05327530
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive sacituzumab govitecan intravenous infusion at dose of 10 milligrams per kilogram (mg/kg) of body weight once a week (Q1W) on Day 1 and 8 of 21-day treatment cycles, in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Study: NCT05327530
Drug: M6223
Normalized name: Metformin hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive M6223 (anti-T cell-immuno-receptor with Ig and ITM domains \[anti-TIGIT\]) intravenous infusion at dose of 1600 mg Q2W in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Study: NCT05085002
Drug: Lerociclib + Letrozole or Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All participants (1L and 2L populations) will receive an AI (letrozole) or fulvestrant plus lerociclib 150 mg BID.
Study: NCT06572761
Drug: Combination of antibiotics
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally
Study: NCT06104683
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06572761
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal progesterone